Non-drug, non-surgical treatment for overactive bladder
Urgent PC delivers percutaneous tibial nerve stimulation (PTNS) to treat patients with overactive bladder and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.
Proven Data – 50 studies demonstrating safety, efficacy and preference to other third line therapies.
Proven Experience – 12 years of clinical use in thousands of clinics around the world and over 1 million treatments with no severe side effects.
Proven Support – product experts with unparalleled knowledge of PTNS.
Urgent PC is a low-risk outpatient treatment for the symptoms of overactive bladder including urinary urgency, urinary frequency and urge incontinence. Urgent PC is also a treatment for fecal incontinence.
Since 2003, healthcare professionals have used the Urgent PC Neuromodulation System as an effective office treatment for men and women suffering from fecal incontinence and overactive bladder. Urgent PC is up to 80% effective, even after behavioral measures and drugs have failed 1-9. Plus, Urgent PC is very low risk, making it a great choice for patients unable or unwilling to have more invasive procedures.
Some LABORIE products may not be available in certain regions.
Please contact your local LABORIE Sales Representative to learn more about the products available to you.
1. Peters, K., Carrico, D. (2013). Clinical insights into percutaneous tibial nerve stimulation (PTNS) versus sham therapy for the treatment of overactive bladder syndrome (OAB): secondary analysis of the SUmiT Trial. Poster presentation, SUFU winter meeting, Las Vegas, NV.
2. Leong, F.C., McLennan, M.T., Barr, S.A., & Steele, A.C. (2011). Posterior tibial nerve stimulation in patients who have failed anticholinergic therapy: efficacy and time to response. Female Pelvic Med Reconstr Surg, 17(2), 74-5.
3. Peters, K.M., Carrico, D.J., Perez-Marrero, R.A., Khan, A.U., Wooldridge, L.S., Davis, G.L., et al. (2010). Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT Trial. J Urol, 183, 1438–43.
4. Peters, K.M., Leong, F.C., Shobeiri, S.A., MacDiarmid, S.A., Rovner, E.S., Wooldridge, L.S., et al. (2009). A randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy trial. J Urol, 182, 1055-61.
5. Vecchioli-Scaldazza, C., Morosetti, C., Beouz, A., Giannubilo, W., Ferrara, V. (2013). Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Invest, 75(4), 230-4.
6. Peters, K.M., Carrico, D.J., Wooldridge, L.S., Miller, C.J. & MacDiarmid, S.A. (2013). Percutaneous tibial nerve stimulation (PTNS) for the long-term treatment of overactive bladder: three-year results of the STEP Study. J Urol, 189(6), 2194-2201.
7. Finazzi-Agrò, E., Petta, F., Sciobica, F., Pasqualetti, P., Musco, S., & Bove, P. (2010). Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol, 184, 2001-06.
8. MacDiarmid, S.A., & Staskin, D.R. (2009). Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. Curr Bld Dysf Rept, 4, 29-33.
9. Burton, C., Sajia, A., & Latthe, P.M. (2012). Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systemic review and meta-analysis. Neurourol Urodyn, 31(8), 1206-16.